Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

Gündüz,Seyda; Göksu,Sema  Sezgin; Arslan,Deniz; Tatli,Ali  Murat; Uysal,Mükremin; Gündüz,Umut  Rıza; Sevinç,Mert  Mahsuni; Coşkun,Hasan  Senol; Bozcuk,Hakan; Mutlu,Hasan; Savas,Burhan

doi:10.3892/mco.2015.610

September-2015 Volume 3 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2015 Volume 3 Issue 5

Full Size Image

Article

Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

Authors:
- Seyda Gündüz
- Sema Sezgin Göksu
- Deniz Arslan
- Ali Murat Tatli
- Mükremin Uysal
- Umut Rıza Gündüz
- Mert Mahsuni Sevinç
- Hasan Senol Coşkun
- Hakan Bozcuk
- Hasan Mutlu
- Burhan Savas
View Affiliations / Copyright

Affiliations: Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya 67070, Turkey, Department of Surgery, Antalya Research and Training Hospital, Antalya 07070, Turkey, Department of Surgery, Istanbul Research and Training Hospital, Istanbul 34000, Turkey
Pages: 1109-1112
|
Published online on: July 21, 2015

https://doi.org/10.3892/mco.2015.610
Expand metrics +

Abstract

Breast cancer is the most frequently diagnosed cancer in women worldwide and the second cause of cancer‑related mortality. A total of 20‑30% of patients with early‑stage breast cancer develop recurrence within the first 5 years following diagnosis. Trastuzumab significantly improves overall survival and disease‑free survival (DFS) in women with human epidermal growth factor receptor 2 (HER2)‑positive early and locally advanced breast cancer. This study aimed to determine the factors that affect DFS following adjuvant transtuzumab therapy. A total of 62 patients treated with trastuzumab for early and locally advanced breast cancer were included in our study. data, including pathology, treatment and treatment outcome, rate of recurrence and laboratory tests, were retrospectively collected. There was no significant association between DFS and age, menopausal status, disease stage and hormone receptor status. The median follow‑up was 48.4 months. The median DFS of patients treated with adjuvant trastuzumab was 64.1 months. In addition, the median DFS was 44.3 vs. 66.8 months in patients with platelet‑lymphocyte ratio (PLR) ≤200 vs. >200, respectively (log‑rank test; P=0.001), and 70 vs. 45 months in patients with eosinophil count ≤70 vs. >70x103̸mm3 (log‑rank test; P=0.001). Our data revealed the prognostic relevance of a decrease in the peripheral blood eosinophil count and PLR value following trastuzumab therapy in breast cancer. PLR and eosinophil count measurements are cost‑effective, readily available worldwide, non‑invasive and safe. Combined with other markers, such as patient age, tumor stage and tumor histology, may be effectively used for patients with breast cancer.

View Figures

View References

1	Jemal A and Bray F: Global Cancer Statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R and DeSantis C: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
3	Brewster AM, Hortobagyi GN, Broglio KR, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 100:1179–1183. 2008. View Article : Google Scholar : PubMed/NCBI
4	Vicente Conesa MA, Garcia-Martinez E, Billalabeitia EG, Benito AC, Garcia TG, Garcia VV and Ayala de la Peña F: Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. The Breast. 21:468–474. 2012. View Article : Google Scholar : PubMed/NCBI
5	Mackall CL, Fleisher TA, Brown MR, et al: Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 84:2221–2228. 1994.PubMed/NCBI
6	Smith I, Procter M, Gelber RD, et al: HERA study team: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gennari R, Menard S, Fagnoni F, et al: Pilot study of the mechanism of action of preoperativetrastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 10:5650–5655. 2004. View Article : Google Scholar : PubMed/NCBI
8	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
9	Nurden AT: Platelets, inflammation and tissue regeneration. Thromb Haemost. 105:(Suppl 1). 13–33. 2011. View Article : Google Scholar : PubMed/NCBI
10	Proctor MJ, Morrison DS, Talwar D, et al: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome study. Eur J Cancer. 47:2633–2641. 2011. View Article : Google Scholar : PubMed/NCBI
11	Feng JF, Huang Y and Liu JS: Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 6:1605–1612. 2013.PubMed/NCBI
12	Papatestas AE, Lesnick GJ, Genkins G and Aufses AH Jr: The prognostic significance of peripheral lymphocyte counts in patients with breast carcinoma. Cancer. 37:164–168. 1976. View Article : Google Scholar : PubMed/NCBI
13	Pattison CW, Woods KL and Morrison JM: Lymphocytopenia as an independent predictor of early recurrence in breast cancer. Br J Cancer. 55:75–76. 1987. View Article : Google Scholar : PubMed/NCBI
14	Ray-Coquard I, Cropet C, Van GM, et al: Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res. 69:5383–5391. 2009. View Article : Google Scholar : PubMed/NCBI
15	Le Scodan R, Massard C, Mouret-Fourme E, et al: Brain metastases from breast carcinoma: validation of the Radiation Therapy Oncology Group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys. 69:839–845. 2007. View Article : Google Scholar : PubMed/NCBI
16	Le Scodan R, Massard C, Jouanneau L, Coussy F, Gutierrez M, Kirova Y, Lerebours F, Labib A and Mouret-Fourme E: Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol. 106:169–176. 2012. View Article : Google Scholar : PubMed/NCBI
17	Delyon J, Mateus C, Lefeuvre D, et al: Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 24:1697–1703. 2013. View Article : Google Scholar : PubMed/NCBI
18	Moja L, Tagliabue L, Balduzzi S, et al: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 4:CD0062432012.PubMed/NCBI
19	Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
20	Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
21	Olson EM, Abdel Rausoul M, Maly J, Wu CS, Lin NU and Shapiro CL: Insidence and risk of central nervous system metastases as site of first recurrence in patients in with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 24:1526–1533. 2013. View Article : Google Scholar : PubMed/NCBI
22	Tsuji W, Teramukai S, Ueno M, Toi M and Inamoto T: Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer. 21:86–95. 2014. View Article : Google Scholar : PubMed/NCBI
23	Clark GM, Sledge GW Jr, Osborne CK and McGuire WL: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 5:55–61. 1987.PubMed/NCBI
24	Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A and Garcia-Conde J: Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 56:67–78. 1999. View Article : Google Scholar : PubMed/NCBI
25	Koenders PG, Beex LV, Kloppenborg PW, Smals AG and Benraad TJ: Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat. 21:173–180. 1992. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles